湖北共同药业股份有限公司 2024 年度独立董事述职报告（夏成才） 本人夏成才作为湖北共同药业股份有限公司（以下简称"公司"）第二届董事 会独立董事，因董事会换届选举于 2024 年 10 月离任。在 2024 年度任职期间，本人 严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 《上市公司独立董事管理办法》等相关法律法规，以及《湖北共同药业股份有限公 司章程》（以下简称"《公司章程》"）、《独立董事工作制度》等相关规定和要 求，本着客观、公正、独立的原则，忠实勤勉地履行独立董事职责，按规定出席相 关会议，认真审议董事会各项议案，充分发挥独立董事的作用，切实维护了公司和 全体股东的合法权益。现将本人 2024 年度履行独立董事职责情况汇报如下： 一、独立董事的基本情况 本人夏成才，1949 年 7 月出生，中国国籍，无境外永久居留权，1982 年毕业于 中国人民大学会计专业，本科学历，系中国注册会计师非执业会员，首届中国管理 会计咨询 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.2400 | 0.2000 | -220 | 0.3488 | | 每股净资产（元） | 0 | 7.43 | -100 | 7.21 | | 每股公积金(元) | 3.56 | 3.56 | 0 | 3.55 | | 每股未分配利润(元) | 2.52 | 2.78 | -9.35 | 2.58 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 5.37 | 5.66 | -5.12 | 6.05 | | 净利润(亿元) | -0.28 | 0.23 | -221.74 | 0.4 | | 净资产收益率(%) | -2.94 | 2.45 | -220 | 4.91 | 数据四舍五入，查看更多财务数据>> 三、分红送配方案情况 不分配不转增 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 2683.27万股，累计占流通股比： ...

Financial Performance - The company's revenue for 2024 is reported at ¥536,595,592.03, a decrease of 5.26% compared to ¥566,399,208.58 in 2023[23]. - The net profit attributable to shareholders for 2024 is a loss of ¥27,591,132.24, representing a decline of 219.94% from a profit of ¥23,005,014.76 in 2023[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is a loss of ¥28,216,624.07 for 2024, down 234.61% from ¥20,961,686.55 in 2023[23]. - The operating cash flow for 2024 is reported at -¥20,588,447.63, a decrease of 130.22% compared to ¥68,132,540.93 in 2023[23]. - The basic earnings per share for 2024 is -¥0.24, a decline of 220.00% from ¥0.20 in 2023[23]. - The total assets at the end of 2024 amount to ¥2,789,880,328.86, an increase of 13.98% from ¥2,447,740,699.18 at the end of 2023[23]. - The net assets attributable to shareholders at the end of 2024 are ¥923,137,679.57, a decrease of 3.11% from ¥952,749,525.16 at the end of 2023[23]. - The company reported a significant drop in weighted average return on equity to -2.94% in 2024 from 2.45% in 2023[23]. - The revenue after deducting certain amounts for 2024 is ¥532,568,105.18, compared to ¥565,501,718.58 in 2023[23]. - The company has indicated uncertainty regarding its ability to continue as a going concern due to negative net profits in recent years[23]. Operating Expenses and Costs - Operating expenses increased compared to the same period last year, mainly due to the expansion of the company's scale and the addition of personnel during the construction period of its subsidiary, leading to higher salary and operational costs[5]. - Financial expenses increased due to the capitalization of interest on convertible bonds and project-specific loans being converted to expenses[5]. - The gross profit margin for steroid raw material manufacturing was 19.67%, down 2.42% from the previous year[59]. - Direct materials accounted for 61.91% of total costs, an increase of 8.25% compared to the previous year[62]. - The net profit attributable to shareholders decreased, resulting in an overall loss due to increased operating costs and R&D expenses[54]. Research and Development - The company has increased its R&D investment to enhance industry technology barriers, resulting in a corresponding rise in R&D expenses[5]. - Research and development expenses increased by 34.08% to ¥51,083,365.27 compared to ¥38,098,898.41 in the previous year[66]. - The company established a dedicated R&D center to enhance innovation efficiency and reduce costs, leading to significant improvements in existing products[56]. - The company plans to enhance its high-end R&D platform and increase investment in new product development to improve product quality and market competitiveness[47]. - The company is focusing on three strategic directions: technological iteration, capacity expansion, and market deepening to strengthen its core position in the steroid drug industry[46]. Market and Industry Trends - The global steroid drug market is experiencing rapid growth, leading to intensified competition and pressure on profit margins, which the company aims to address through continuous R&D investment and strategic collaborations[7]. - The global steroid drug market has reached hundreds of billions of dollars, with expectations for continued high growth due to widespread applications in treating various diseases[35]. - The domestic steroid drug market is also experiencing significant growth, driven by an expanding pharmaceutical market and increasing demand for treatments related to endocrine disorders and inflammatory diseases[35]. - The company operates in the pharmaceutical manufacturing sector, focusing on the research, production, and sales of steroid drug raw materials[32]. Corporate Governance - The company has established a mature governance structure with a separation of powers among the shareholders' meeting, board of directors, supervisory board, and management team[88]. - The company emphasizes compliance and risk management, planning to enhance its operational system and processes through digital transformation initiatives[88]. - The company held 1 annual shareholders' meeting and 3 temporary shareholders' meetings during the reporting period, ensuring compliance with relevant regulations[94]. - The board of directors held 12 meetings, with a composition of 7 members including 3 independent directors, adhering to legal and regulatory requirements[96]. - The company has established a performance evaluation and incentive mechanism for senior management, linking their compensation to the company's operational performance[99]. Environmental Responsibility - The company strictly adheres to environmental protection policies and has obtained necessary environmental impact assessments and permits for its projects[143]. - The company has implemented a wastewater treatment system that follows the principle of "rainwater and sewage separation" and ensures compliance with discharge standards[147]. - The company utilizes a comprehensive air pollution control process including alkaline spraying, water spraying, and regenerative thermal oxidation (RTO) for emissions[147]. - The company has established a complete hazardous waste management system, including a dedicated storage area and compliance with relevant regulations[147]. - The company reported no exceedances in pollutant emissions for major pollutants monitored[146]. Employee Management and Development - The total number of employees at the end of the reporting period is 817, with 157 in the parent company and 660 in major subsidiaries[130]. - The professional composition includes 428 production personnel, 17 sales personnel, 143 technical personnel, 16 financial personnel, and 213 administrative personnel[130]. - The company has established a comprehensive salary system and incentive mechanism to ensure employee interests, including basic salary and performance bonuses[131]. - The company emphasizes the output and contribution of research personnel, providing project incentive bonuses based on project completion[132]. - The company conducts a "Sailing Plan" talent development program to enhance employee capabilities and professional quality[133]. Strategic Initiatives - The company aims to enhance its competitive edge through technology, product, customer, and management advantages for long-term healthy development[6]. - The company is optimizing its product structure to meet the evolving demands of downstream steroid drug manufacturers, which may lead to higher costs and lower gross margins during the trial production phase[10]. - The company has established a market-driven marketing system to enhance its competitive edge throughout the product lifecycle[52]. - The company aims to build a comprehensive quality network covering R&D, production, and warehousing, with ongoing preparations for compliance checks and certifications[53]. - The company aims to enhance its core competitiveness through continuous technological innovation and product development, focusing on "technology leadership, capacity upgrading, and green transformation"[84].

上市公司 2024 年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司 | 年期 2024 | 年度占用 2024 | 年度占 2024 | 2024年度偿还 | 年期末 2024 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 核算的会计科目 | 初占用资 | 累计发生金额 | 用资金的利息 | 累计发生金额 | 占用资金余 | 原因 | | | | | | | 金余额 | （不含利息） | （如有） | | 额 | | | | 控股股东、实际控制 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 非经营性占用 | | 人及其附属企业 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 非经营性占用 | | 小计 | | | | | | | | | | | | 前控股股东、实际控 | -- | -- | ...

主管会计工作负责 | | | 合并资产负债表 | | | | | --- | --- | --- | --- | --- | --- | | 编制单位:湖北共同药业 | | | 2024 年 12月 31 日 | | 单位:人民币元 | | | | | 附注 | 2024 年 12月 31 日 | 2024年1月1日 | | 流动资产: | | | | | | | 货币资金 | | | | 141, 181, 205. 23 | 181, 973, 811. 45 | | 交易性金融资产 | | | | 1, 010. 63 | 1, 010. 45 | | 衍生金融资产 | | | | | | | 应收票据 | | | | 15, 969, 258. 05 | 9, 502, 405. 17 | | 应收账款 | | | | 188, 668, 396. 08 | 210, 199, 485. 52 | | 应收款项融资 | | | | 9, 623, 992. 21 | 15, 694, 632. 58 | | 预付款项 | | | | 10, 721, 612. 30 | 19, 796, 737. 0 ...

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-022 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 | 关联交易类别 | 关联人 | 关联交易 | 关联交易 | 合同签订金额 | | 截至披露日 | 上年发 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 内容 | 定价原则 | 或预计金额 | | 已发生金额 | 生金额 | | 向关联人采购 商品 | 同新药业 | 原材料 | 市场价格 | 不超过 | 1,000 | 107.85 | 89.73 | | 向关联人销售 商品 | 同新药业 | 甾体药物 起始物料 | 市场价格 | 不超过 | 3,000 | 376.02 | 522.04 | 关于公司及子公司 2025 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 湖北共同药业股份有限公司（以下简称"共同药业"或"公司"）根据《中华 人民共和国公司法 ...

2024 年年度报告披露提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 湖北共同药业股份有限公司（以下简称"公司"）于 2025 年 4 月 22 日召开第 三届董事会第五次会议和第三届监事会第四次会议，审议通过了《关于〈公司 2024 年年度报告〉及其摘要的议案》。 | 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-018 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 湖北共同药业股份有限公司 为使投资者全面了解公司的经营成果、财务状况及未来发展规划，公司在巨潮 资讯网（www.cninfo.com.cn）披露了《2024 年年度报告》（公告编号：2025-019） 和《2024 年年度报告摘要》（公告编号：2025-020），敬请投资者查阅。 特此公告。 2025 年 4 月 22 日 董事会 ...

湖北共同药业股份有限公司 2024 年度董事会工作报告 2024 年，湖北共同药业股份有限公司（以下简称"公司"）董事会在全体董事 的共同努力下，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共国证券法》（以下简称"《证券法》"）、《湖北共同药业股份有限公司 章程》（以下简称"《公司章程》"）、《深交所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》、《湖北共同药业股份有限公司董事会议事规则》（以 下简称"《董事会议事规则》"）等法律、法规及公司内部制度的规定，本着对全 体股东负责的态度，恪尽职守、诚实守信、勤勉尽责地履行义务及行使职权，认真 贯彻落实公司股东大会各项决议，有效开展董事会各项工作，不断完善公司治理， 提升规范运作水平，保障了公司良好运作和可持续发展，维护了公司及股东的合法 权益。现将董事会 2024 年度工作情况汇报如下： 一、公司总体经营概况 报告期内，公司实现营业总收入 536,595,592.03 元，较上年同期下降 5.26%；归 属于上市公司股东的净利润为-27,591,132.24 元，较上年同期下降 219.94%；归属于 上市公司股东的扣除非经 ...

您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查导 报告编码:京25K8XEWTTN 1 22 层 2206 湖北共同药业股份有限公司 非经营性资金占用及其他关联资金往 来情况汇总表的专项审计报告 大信专审字【2025】第 5-00045 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. WUYIGE Certified Public Accountants.LLP 路 1 号 Room 2206 22/F, Xueyuan International Tower No.1 Zhichun Road. Haidian Dist. Beijing. China. 100083 电话 Telenhone: +86(10) 82330558 +86 (10) 82327668 www.daxincpa.com.cn xx til- Internet 非经营性资金占用及其他关联资金往来情况汇总表的 专项审计报告 大信专审字[2025]第 5-00045 号 湖北共同药业股份有限公司全体股 ...

湖北共同药业股份有限公司 2024年12月31日内部控制评价报告 湖北共同药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求 （以下简称企业内部控制规范体系），结合湖北共同药业股份有限公司（以下简称"共 同药业"、"公司"）内部控制制度和评价办法，在内部控制日常监督和专项监督的基 础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性 进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效 性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实 施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、 监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假记载、误导性 陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法律责 任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关 信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在固有 局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化可 ...